Lily Of The Valley (Herb/Suppl)

Brand and Other Names:Convallaria majalis, Jacob's Ladder, more...May Bells, May Lily
  • Print

Suggested Dosing

Cardiac Glycosides

Insufficient reliable evidence available for effectiveness

600 mg/day PO average amount

Tincture: 6 g/day divided TID PO

Liquid extract: 600 mg/day divided TID PO

Dried extract: 150 mg/day PO

Next:

Suggested Uses

Circulatory disorders, heart palpitations, arrhythmia, CHF, cardiac edema, cardiac asthma, kidney and bladder stones, UTI

Efficacy

Contains cardiac glycosides similar to those in digitalis

Previous
Next:

Interactions

Interaction Checker

and Lily Of The Valley

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • digoxin

                digoxin, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated.

              Monitor Closely (13)

              • bendroflumethiazide

                bendroflumethiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • bumetanide

                bumetanide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • chlorothiazide

                chlorothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • chlorthalidone

                chlorthalidone increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • cyclopenthiazide

                cyclopenthiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • ethacrynic acid

                ethacrynic acid increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • furosemide

                furosemide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • hydrochlorothiazide

                hydrochlorothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • indapamide

                indapamide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • methyclothiazide

                methyclothiazide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • metolazone

                metolazone increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • senna

                senna increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              • torsemide

                torsemide increases toxicity of lily of the valley by Other (see comment). Use Caution/Monitor. Comment: Increased risk of cardiac toxicity due to K+ depletion.

              Minor (23)

              • acebutolol

                acebutolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • adenosine

                adenosine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • amiodarone

                amiodarone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • calcium acetate

                calcium acetate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

              • calcium carbonate

                calcium carbonate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

              • calcium chloride

                calcium chloride increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

              • calcium citrate

                calcium citrate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

              • calcium gluconate

                calcium gluconate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

              • diltiazem

                diltiazem, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • disopyramide

                disopyramide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • encainide

                encainide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • esmolol

                esmolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • flecainide

                flecainide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • ibutilide

                ibutilide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • lidocaine

                lidocaine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • mexiletine

                mexiletine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • phenytoin

                phenytoin, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • procainamide

                procainamide, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • propafenone

                propafenone, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • propranolol

                propranolol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • quinidine

                quinidine, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • sotalol

                sotalol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              • verapamil

                verapamil, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

              Previous
              Next:

              Warnings

              Contraindications

              High BP, kidney/liver disease, potassium deficiency

              Pregnancy

              Cautions

              Use only under qualified supervision: potentially fatal if overdosed

              Taking more than recommended dose may cause nausea, vomiting, headache, stupor, disorders of color perception, and irregular heartbeat

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: avoid

              Lactation: N/A

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Cardiac glycosides increase force and power of heartbeat without increasing amount of oxygen required by cardiac muscle

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.